Coronary Artery Disease and Fibrinolysis: From the Blood to the Vessel Wall

Summary

This review addresses a continuum of the role of derangements in the fibrinolytic system from the blood to the vessel wall in the pathogenesis of acute coronary events and the underlying vasculopathy. Pharmacologic modification of fibrinolysis has become a primary therapy for acute myocardial infarction caused by thrombotic occlusion of infarct-related coronary arteries. Patients with type 2 diabetes and other insulin resistant states exhibit impaired fibrinolysis in blood, implicated in the pathogenesis of macroangiopathy. An altered balance of activity of proteins involved in the fibrinolytic system within vessel walls (the proteo[fibrino]lytic system) has been recognized as well and appears likely to contribute to the acceleration of macroangiopathy. Accordingly, normalization of the proteo(fibrino)lytic system in blood and in vessel walls is a particularly attractive target for retardation of the progression of macrovascular disease associated with insulin resistant states.

Key words

PAI-1 - tPA - clot lysis - thrombosis - atherosclerosis - plaque vulnerability

• References

• 1 Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross Jr. J, Braunwald E. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 1971; 43: 67-82.
• 2 Shell WE, Sobel BE. Protection of jeopardized ischemic myocardium by reduction of ventricular afterload. N Engl J Med 1974; 291: 481-6.
• 3 Roberts R, Croft C, Gold HK, Hartwell TD, Jaffe AS, Muller JE, Mullin SM, Parker C, Passamani ER, Poole WK, Raabe Jr. DS, Rude RE, Stone PH, Turi ZG, Sobel BE, Willerson JT, Braunwald E. and the MILIS Study Group. Effect of propranolol on myocardial infarct size in a randomized, blinded, multicenter trial. N Engl J Med 1984; 311: 218-25.
• 4 Bergmann SR, Lerch RA, Fox KAA, Ludbrook PA, Welch MJ, Ter-Pogossian MM, Sobel BE. Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med 1982; 73: 573-81.
• 5 Chazov EL, Matteeva LS, Mazaev AV, Sargin KE, Sadovshaya M, Ruda Y. Intracoronary administration of fibrinolysis in acute myocardial infarction. Ter Arkh 1976; 48: 8-19.
• 6 Rentrop P, Blanke H, Karsch DR, Kaiser H, Kosterling H, Leitz K. Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation 1981; 63: 307-17.
• 7 Gruppo Italiano Per Lo Studio Della Streptochinasi Nell'infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-401.
• 8 Collen D, Rijken DC, Van Damme J, Billiau A. Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo. Thromb Haemost 1982; 48: 294-6.
• 9 Collen D, Stassen JM, Marafino BJ, Builder S, De Cock F. et al. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J Pharmacol Exp Ther 1984; 231: 146-52.
• 10 Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest 1983; 71: 368-76.
• 11 Collen D, Stump DC, Gold HK. Thrombolytic therapy. Annu Rev Med 1988; 39: 405-23.
• 12 Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML. et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 1984; 70: 1012-1017.
• 13 Torr SR, Nachowiak DA, Fujii S, Sobel BE. “Plasminogen steal” and clot lysis. J Am Coll Cardiol 1992; 19: 1085-90.
• 14 Sobel BE. Coronary thrombolysis: Background and factors underlying its emergence. In: Coronary Thrombolysis in Perspective. Principles Underlying Conjunctive and Adjunctive Therapy. Sobel BE, Collen D. eds New York: Marcel Dekker; 1993: 1-10.
• 15 Sobel BE. Thrombolysis in the treatment of acute myocardial infarction. In: Thrombosis in Cardiovascular Disorders. Fuster V, Verstraete M. eds Philadelphia: W.B. Saunders Company; 1992: 289-326.
• 16 Eisenberg PR, Sherman L, Rich M, Schwartz D, Schechtman K, Geltman EM, Sobel BE, Jaffe AS. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986; 7: 1255-62.
• 17 Sobel BE, Nachowiak DA, Fry ETA, Bergmann SR, Torr SR. Paradoxcial attenuation of fibrinolysis attributable to “plasminogen steal” and its implications for coronary thrombolysis. Coron Artery Dis 1990; 1: 111-19.
• 18 Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation 1996; 93: 1328-30.
• 19 Bajzar L, Morser J, Nesheim M. Purigication and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 270: 14477-84.
• 20 Bajzar L, Nesheim M, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
• 21 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-08.
• 22 Battle RW, Sobel BE. Coronary thrombolysis for treatment of acute myocardial infarction. In: Cardiac Intensive Care. Brown D. ed Philadelphia: W. B. Saunders; 1998: 133-60.
• 23 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Eng J Med 1992; 329: 1615-22.
• 24 Shatos MA, Doherty JM, Penar PL, Sobel BE. Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators: A factor potentially predisposing to intracranial bleeding. Circulation 1996; 94: 636-42.
• 25 Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. 5-Year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 1990; 82: 27-36.
• 26 Stolar MW. Atherosclerosis in diabetes: the role of hyperinsulinemia. Metabolism 1998; 37: 1-9.
• 27 Haffner SM. The insulin resistance syndrome revisited. Diabetes Care 1996; 19: 275-7.
• 28 Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-7.
• 29 Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997; 47: 1354-9.
• 30 Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993; 92: 141-6.
• 31 Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb 1992; 12: 647-56.
• 32 Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease. The Framingham experience. Am Heart J 1990; 120: 672-6.
• 33 Schneider DJ, Sobel BE. Effect of diabetes on the coagulation and fibrinolytic systems and their implications for atherogenesis. Coron Artery Dis 1992; 3: 26-32.
• 34 Schneider DJ, Sobel BE. Determinants of coronary vascular disease in patients with type II diabetes mellitus and their therapeutic implications. Clin Cardiol 1997; 20: 433-40.
• 35 Hofmann MA, Kohl B, Zumbach MS, Borcea V, Bierhaus A, Henkels M, Amiral J, Fiehn W, Ziegler R, Wahl P, Nawroth PP. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1997; 201: 880-6.
• 36 Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MD, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-3.
• 37 Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C. Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metabolisme 1987; 13: 331-6.
• 38 Keber I, Keber D. Increased plasminogen activator inhibitor activity in survivors of myocardial infarction is associated with metabolic risk factors of atherosclerosis. Haemostas 1992; 22: 187-94.
• 39 Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity. Arterioscler Thromb Vasc Biol 1998; 18: 1-6.
• 40 Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. J Clin Invest 1996; 97: 37-46.
• 41 Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Molecular Medicine 1996; 2: 568-82.
• 42 Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and athero-thrombosis. Diabetologia 1991; 34: 457-62.
• 43 Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994; 72: 44-53.
• 44 McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43: 104-9.
• 45 Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: A potential risk factor for vascular disease. Circulation 1994; 89: 321-30.
• 46 Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2108-26.
• 47 Schneider DJ, Sobel BE. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids. Coron Artery Dis 1996; 7: 813-7.
• 48 Loskutoff DJ, van Aken BE, Seiffert D. Abnormalities in the fibrinolytic system of the vascular wall associated with atherosclerosis. Ann NY Acad Sci 1995; 748: 177-183.
• 49 Lundgren CH, Sawa H, Brown SL, Nordt T, Sobel BE, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes: A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93: 106-110.
• 50 Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisligil GS, Loskutoff DJ. Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 1999; 96: 6902-7.
• 51 Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18: 1-6.
• 52 Taatjes DJ, Wadsworth M, Absher PM, Sobel BE, Schneider DJ. Immuno-electron microscopic localization of plasminogen activator inhibitor type 1 (PAI-1) in smooth muscle cells from morphologically normal and atherosclerotic human arteries. Ultrastruct Pathol 1997; 21: 527-36.
• 53 Loskutoff DJ, van Aken BE, Seiffert D. Abnormalities in the fibrinolytic system of the vascular wall associated with atherosclerosis. Ann New York Acad Sci 1995; 748: 177-83.
• 54 Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type-1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: A potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97: 2213-21.
• 55 Schneider DJ, Ricci MA, Taatjes DJ, Baumann PQ, Reese JC, Leavitt BJ, Absher M, Sobel BE. Changes in arterial expression of fibrinolytic system proteins in atherogenesis. Arterioscler Thromb Vasc Biol 1997; 17: 3294-301.
• 56 Clowes AW, Clowes MM, Au YP, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-7.
• 57 Knox JB, Sukhova GK, Whittemore AD, Libby P. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 1997; 95: 205-12.
• 58 Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy: A reconcilable paradox. Circulation 1999; 99: 2496-8.
• 59 BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Eng J Med 1996; 335: 217-25.
• 60 Rozenman Y, Sapoznikov D, Mosseri M, Gilon D, Lotan C, Nassar H, Weiss AT, Hasin Y, Gotsman MS. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigation. J Am Coll Cardiol 1997; 30: 1420-5.
• 61 Carrozza JP, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Int Med 1993; 118: 344-9.
• 62 Minamikawa J, Yamauchi M, Inoue D, Koshiyama H. Another potential use of troglitazone in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998; 83: 1041-2.
• 63 Balkau B, Eschwege E, Tichet J, Marre M. Proposed criteria for the diagnosis of diabetes: evidence from a French epidemiological study (D.E.S.I.R.). Diabetes Metab 1997; 23: 428-34.
• 64 Haffner SM, Mykkanen L, Valdez RA, Stern MP, Holloway DL, Monterrosa A, Bowsher RR. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab 1994; 79: 1806-10.
• 65 Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7.